Compare STBA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | FTRE |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2023 |
| Metric | STBA | FTRE |
|---|---|---|
| Price | $39.85 | $9.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $43.00 | $15.39 |
| AVG Volume (30 Days) | 239.7K | ★ 1.6M |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $4.14 | $2.96 |
| P/E Ratio | $11.50 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $30.84 | $3.97 |
| 52 Week High | $44.91 | $18.67 |
| Indicator | STBA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 37.37 |
| Support Level | $38.89 | $9.05 |
| Resistance Level | $40.42 | $11.22 |
| Average True Range (ATR) | 1.07 | 0.67 |
| MACD | -0.18 | 0.20 |
| Stochastic Oscillator | 19.23 | 35.96 |
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.